Tech Company Financing Transactions
Intarcia Therapeutics Funding Round
Intarcia Therapeutics closed a $75 million funding round on 5/6/2016. Investors included MidCap Financial and Silicon Valley Bank.
Transaction Overview
Company Name
Announced On
5/6/2016
Transaction Type
Debt
Amount
$75,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The company will use the proceeds to ramp up manufacturing to build inventory for a prospective late 2017 commercial launch.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
1 Marina Park Dr. 13 Floor
Boston, MA 02210
USA
Boston, MA 02210
USA
Phone
Website
Email Address
Overview
Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company committed to developing innovative therapies that merge medicine with technology, and have the potential to transform therapeutic categories.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Kurt Graves
Chief Scientific Officer
Andrew Young
VP - Client Services
Jay Smith
VP - General Counsel
Raymond Keane
VP - Human Resources
James Brady
VP - Manufacturing
Thomas Alessi
Browse more venture capital transactions:
Prev: 5/6/2016: YieldStreet venture capital transaction
Next: 5/6/2016: ACT Genomics venture capital transaction
Share this article
News on VC Transactions
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs